

# Lessons learnt conducting minimally-invasive autopsies in private mortuaries as part of HIV and tuberculosis research in South Africa

---

Aaron S Karat<sup>1</sup>, Tanvier Omar<sup>2</sup>, Mpho Tlali<sup>3</sup>, Salome Charalambous<sup>3,4</sup>, Violet N Chihota<sup>3,4</sup>, Gavin J Churchyard<sup>1,3,4</sup>, Katherine L Fielding<sup>1,4</sup>, Neil A Martinson<sup>5,6,7</sup>, Kerrigan M McCarthy<sup>3,4,8</sup>, Alison D Grant<sup>1,4,9</sup>

## Running head

Conducting autopsies in private mortuaries

## Author affiliations

1. TB Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom
2. Division of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa
3. The Aurum Institute, Johannesburg, South Africa
4. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5. Perinatal HIV Research Unit, and South African Medical Research Council Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa
6. Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of America
7. Department of Science and Technology / National Research Foundation Centre of Excellence for Biomedical TB Research, University of the Witwatersrand, Johannesburg, South Africa
8. Division of Public Health, Surveillance and Response, National Institute for Communicable Disease of the National Health Laboratory Service, Johannesburg, South Africa
9. Africa Health Research Institute, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa

## Corresponding author

Dr Aaron Karat, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.  
Telephone: +44 (0)20 7636 8636 | Email: [aaron.karat@lshtm.ac.uk](mailto:aaron.karat@lshtm.ac.uk)

## Word counts

Summary: 122 words; Main text 1,842 words; References: 13; Tables: 1; Figures: 1

33 **SUMMARY**

---

34 Current estimates of tuberculosis disease burden and cause-specific mortality in HIV-positive people rely  
35 heavily on indirect methods, which are less reliable for ascertaining individual-level causes of death, and  
36 mathematical models. Minimally-invasive autopsy (MIA) is useful for diagnosing infectious diseases,  
37 provides a reasonable proxy for the gold standard in cause of death ascertainment (complete diagnostic  
38 autopsy) and, used routinely, could improve cause-specific mortality estimates. From our experiences  
39 performing MIAs in HIV-positive adults in private mortuaries in South Africa (during the *Lesedi Kamoso*  
40 study), we describe the challenges we faced and make recommendations for the conduct of MIA in future  
41 studies or surveillance programmes, including strategies for effective communication, approaches to  
42 obtaining informed consent, risk management for staff, and efficient preparation for the procedure.

43 **Key words**

44 Research design; Mortality; Public health; Methods; Tuberculosis

## 45 **SETTING**

---

46 Tuberculosis (TB) is likely the leading cause of death (CoD) in HIV-positive people and is often under-  
47 recognised as a cause of morbidity.<sup>1</sup> Estimating TB mortality is challenging: current estimates depend  
48 heavily on death certificates, which are often inaccurate in HIV-positive people;<sup>2</sup> verbal autopsy, which  
49 differentiates poorly between TB and other HIV-associated CoD;<sup>3</sup> and mathematical modelling.<sup>4</sup> Complete  
50 diagnostic autopsy is the gold standard for determining CoD, but rates are declining worldwide;<sup>5</sup> minimally-  
51 invasive autopsy (MIA), however, performs well in diagnosing infectious disease<sup>6</sup> and is faster, technically  
52 easier, more portable, probably cheaper, and more acceptable to individuals and families.<sup>7</sup> Most autopsy  
53 studies have included only individuals dying in health facilities<sup>1</sup> and are poorly representative of most high  
54 TB burden countries, where many deaths occur in the community.

55 A community-based MIA surveillance programme at sentinel sites would improve quantification of disease  
56 burden and mortality estimates, but any such venture would encounter many challenges. From mid-2013 to  
57 late 2016, we conducted an MIA study in South Africa (*Lesedi Kamoso* ["light for the future"]) to estimate 1)  
58 the autopsy prevalence of TB and other infections<sup>8</sup> and 2) CoD<sup>9</sup> in HIV-positive adults who died after  
59 enrolment into a trial of empirical TB treatment ("TB Fast Track").<sup>10</sup> Based on our experiences conducting  
60 MIAs in private mortuaries and using information collated from field notes and discussions with the research  
61 team, we describe how challenges were overcome and provide guidance for those planning similar studies  
62 or considering incorporating MIA into surveillance programmes. We do not discuss technicalities of the MIA  
63 procedure, as detailed guidance has been published by other groups.<sup>11,12</sup> The parent and sub-study received  
64 ethical approval from the research ethics committees of The University of the Witwatersrand, the London  
65 School of Hygiene & Tropical Medicine, and local health authorities.

## 66 **ASPECTS OF INTEREST**

---

### 67 **Preparation**

68 Three to six months before data collection begins, the proposed autopsy activity should be discussed with  
69 local stakeholders (Figure 1), including community, traditional, and religious leaders; the police; patient

70 advocates; mortuary owners; managers of local clinics and hospitals; and, ideally, a representative of the  
71 Department of Health. We suggest providing a plain-language written summary, in local languages, with  
72 contact details of key personnel and oversight bodies. Meetings should be held at regular intervals for the  
73 duration of the programme, allowing for findings to be shared and for stakeholders to discuss concerns.

74 Ideally, this preparation period should also include formative work, conducted by social scientists, to gain a  
75 deeper understanding of the dynamics within the community, burial and cremation practices, and beliefs  
76 around death, dying, and autopsy. The scope of religious beliefs and practices should also be explored.  
77 Information collected during the formative work should inform the design of participant information sheets,  
78 the routes by which participants and families are approached, and the training of staff in obtaining consent  
79 and counselling individuals and families.

#### 80 **Death notification**

81 We were largely reliant on family members informing clinic-based research staff of the death of a  
82 participant. On most occasions (229 [79%] of 289 deaths), notification occurred after burial and an autopsy  
83 could not be completed. We observed that the likelihood of timely notification depended on the trust  
84 between the clinic-based researcher and the participant/their family: researchers were more likely to be  
85 informed in time if they were seen as supportive and understanding, and particularly if they were regularly  
86 'checking in' (sometimes informally) on the health of the participant.

#### 87 **Informed consent**

88 Whenever possible, we requested consent for MIA from participants at enrolment to the parent trial: of  
89 2,200 participants asked, 1,675 (76%) agreed; participants were not offered a financial incentive for  
90 participation. We approached the family for permission to proceed if the decedent had consented to MIA at  
91 enrolment or for written consent if the decedent had not been asked (the MIA sub-study was initiated some  
92 months after the start of the parent study and therefore some participants were not asked to consent to

93 MIA at enrolment). If a decedent had declined to consent at enrolment, the family was not approached. Of  
94 43 families approached, 36 (84%) gave consent for MIA.

95 We developed consent procedures after discussion with clinical research experts in South Africa, including  
96 those previously involved in autopsy studies. It should be noted that these procedures were considered  
97 suitable for a study involving adults only; studies or programmes that involve children will entail different  
98 considerations and consent processes should be formulated after consultation with relevant experts.

99 Investigators must be familiar with local legislation around human tissue research, adhere to informed  
100 consent guidelines published by professional and regulatory bodies, and are advised to consult local experts  
101 and institutional review boards. The recommendations below are intended to improve communication  
102 during the consent-taking process (a common reason for initial refusal of consent in our study was  
103 misunderstanding of the purpose of autopsy; for example, we were frequently asked to justify the need for  
104 further examination when the person had already died). As in all health research, participants or families  
105 giving consent should be allowed to make an informed decision about their own or their relative's  
106 participation and all parties must be made aware that they are free to decline or withdraw consent at any  
107 point without risk of immediate or deferred consequences.

108 The experiences of staff and our fieldnotes suggest that individuals enrolled into the parent study were more  
109 likely to consent to MIA if a researcher could discuss MIA in an open and transparent manner; had a good  
110 understanding of the purpose of autopsy in a research context; and was willing to discuss broader topics,  
111 such as life after death. An individual consenting to MIA for themselves was also made more likely by the  
112 involvement of a family member in the consent process, availability of additional plain-language written  
113 information, and availability of a staff member for follow-up conversations (some individuals came back to  
114 give consent for MIA at a later date, or simply wanted to continue the conversation with the researcher).

115 The process for getting consent or permission from the family of a deceased individual may be complicated  
116 by pre-existing tensions within the family; we found it helpful to make our discussions as inclusive as

117 possible and took particular care to communicate with senior family members. On some occasions we had  
118 to make two or three visits to a household before a final decision was made. Families were not offered a  
119 financial incentive for participation, though they were often (informally) assisted with transport to and from  
120 the mortuary on the day of the MIA. Among families who gave permission, we observed that decision-  
121 making family members understood the MIA procedure and the purpose of the study; the discussion took  
122 place some days before the funeral, with reassurance that MIA would not delay proceedings; and, most  
123 importantly, the researcher(s) had a good understanding of the relevant cultural norms and were able to  
124 listen, empathise, and give families space and time for discussion.

125 To our surprise, on more than one occasion a family member requested to observe the autopsy and  
126 reported afterwards that they found it a positive experience; however, this was not the norm, and  
127 acceptability of this practice may be very different in other settings, depending on local expectations and  
128 beliefs, underpinning the need for a robust understanding of the context in which MIAs are to be conducted.  
129 In addition, almost all individuals enrolled into our study were from a Christian background, and the funeral  
130 often did not take place for a week or more after death, giving us time to obtain permission and complete  
131 the MIA. This too may be very different in other settings, and may result in a smaller window in which the  
132 MIA can be conducted; the success of an MIA programme in such settings is likely to depend on the  
133 existence of a strong death notification system, ideally one integrated into hospitals.

#### 134 **Interactions with hospitals and mortuaries**

135 Many private mortuaries in South Africa have informal agreements with hospital staff to facilitate the rapid  
136 transfer of the deceased from hospital to mortuary; often these are well-established networks with financial  
137 implications for those involved. Our experiences suggest that attempts to conduct MIAs in hospitals are  
138 unlikely to succeed unless clear instructions are issued and enforced by senior hospital management or  
139 unless the MIA programme is integrated into hospital procedures.

140 In our study, all MIAs were conducted in private mortuaries; most mortuary staff were helpful and  
141 welcoming, though we did encounter some opposition: twice we were unable to complete the MIA. As  
142 described above and in Figure 1, early engagement with mortuary managers, with opportunities for  
143 questions and clarification, would have made these interactions considerably easier; however, our study was  
144 conducted over a wide geographical area that included several hundred mortuaries, and we were not able to  
145 do this. On the day of the MIA, we advise that, if possible, researchers travel to the mortuary accompanied  
146 by a senior family member to facilitate direct communication between the family and mortuary staff.  
147 Providing mortuaries with written information and contact details of study personnel helped establish trust  
148 and made future interactions considerably easier; over the course of the study, we developed relationships  
149 with some mortuary managers, and would visit mortuaries on days when autopsies were not being  
150 conducted to update them on the study's progress.

#### 151 **Other considerations**

152 Sterile instruments and procedures are not needed if conducting only histological examination of samples;  
153 however, we wished to perform aerobic and mycobacterial culture on samples, but had no access to an  
154 autoclave and encountered difficulties when trying to establish and maintain sterile fields. Useful items of  
155 equipment, including those used to maintain asepsis in the field, are listed in Table 1. All waste generated  
156 during MIA should be considered potentially infectious: many private mortuaries do not have procedures for  
157 clinical waste disposal, so we transported waste to a nearby health facility where this could be done safely.  
158 The World Health Organization provides guidance for transporting potentially infectious materials.<sup>13</sup>

159 To minimise risk during MIA, staff (four research assistants and a driver, in our study) should be trained in  
160 safe practices; educated about potential risks; and advised of the importance of knowing their own HIV  
161 status. These procedures should, ideally, be embedded within an occupational health programme: all staff  
162 should undergo regular screening for active TB and staff who are HIV positive should be made aware of their  
163 increased risk of TB and encouraged to take antiretroviral therapy. In addition, at regular intervals during  
164 the study, we organised debriefing sessions, led by a psychologist, to discuss issues arising from conducting

165 autopsies and dealing with bereaved families, and to provide team members with tools to manage stress  
166 and avoid burnout.

## 167 **CONCLUSIONS**

---

168 MIA, used in routine surveillance, could improve estimates of disease burden and cause-specific mortality,  
169 but the barriers to effective deployment should not be underestimated. If autopsies are to be more widely  
170 conducted outside of hospitals, health professionals and research organisations will need to engage  
171 wholeheartedly with the communities in which they work and strive to understand local beliefs and  
172 practices around death. Thorough preparation, education, transparency, respect, trust, and partnership  
173 with communities will be central to this process.

## 174 **ACKNOWLEDGMENTS**

---

175 We are grateful to the individuals and their families who gave their consent for autopsy and to mortuary  
176 owners and staff. Our thanks to the TB Fast Track team and the Lesedi Kamoso team: Mphonyana Motsatsi,  
177 Bongani Nkaqa, Zanele Nthebe, Khethekile Ntsontso, Monde Phasha, and Thabo Setimela. Thanks also to Dr  
178 Jasantha Odayar for critically reviewing a version of this manuscript.

## 179 **FUNDING**

---

180 Lesedi Kamoso was funded by a grant from the Bill & Melinda Gates Foundation (OPP1083118). The funders  
181 had no role in the design of the study; in the collection, analysis, and interpretation of data; in the writing of  
182 the report; or in the decision to submit for publication.

## 183 **AUTHOR CONTRIBUTIONS**

---

184 All authors were involved in conducting the study, in either an operational or oversight capacity. ASK wrote  
185 the first draft of the manuscript and developed the figure. All authors critically reviewed and made edits to  
186 the manuscript, and all authors gave their permission for submission. The authors declare no conflicts of  
187 interest.




- 189 1 Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected  
190 adults and children in resource-limited settings: a systematic review and meta-analysis. *AIDS*.  
191 2015;**29**(15):1987–2002.
- 192 2 Liu TT, Wilson D, Dawood H, Cameron DW, Alvarez GG. Inaccuracy of death certificate diagnosis of tuberculosis  
193 and potential underdiagnosis of TB in a region of high HIV prevalence. *Clin Dev Immunol*. 2012;**2012**:937013.
- 194 3 Cain KP, Shah NS. (Not) measuring in the dark. *Int J Tuberc Lung Dis*. 2015;**19**(11):1270.
- 195 4 Glaziou P, Dodd PJ, Zignol M, Sismanidis C, Floyd K. Methods used by WHO to estimate the Global burden of TB  
196 disease. 2018.  
197 [https://www.who.int/tb/publications/global\\_report/gtbr2018\\_online\\_technical\\_appendix\\_global\\_disease\\_bur](https://www.who.int/tb/publications/global_report/gtbr2018_online_technical_appendix_global_disease_burden_estimation.pdf?ua=1)  
198 [den\\_estimation.pdf?ua=1](https://www.who.int/tb/publications/global_report/gtbr2018_online_technical_appendix_global_disease_burden_estimation.pdf?ua=1) (accessed 2019 Jan 9)
- 199 5 Mudenda V, Lucas S, Shibemba A, et al. Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa:  
200 the urgent need to expand and invest in routine and research autopsies. *J Infect Dis*. 2012;**205 Suppl**(Suppl  
201 2):S340-6.
- 202 6 Martínez MJ, Massora S, Mandomando I, et al. Infectious cause of death determination using minimally invasive  
203 autopsies in developing countries. *Diagn Microbiol Infect Dis*. 2016;**84**(1):80–6.
- 204 7 Byass P. Minimally Invasive Autopsy: A New Paradigm for Understanding Global Health? *PLoS Med*.  
205 2016;**13**(11):e1002173.
- 206 8 Karat AS, Omar T, von Gottberg A, et al. Autopsy prevalence of tuberculosis and other potentially treatable  
207 infections among adults with advanced HIV enrolled in out-patient care in South Africa. *PLoS One*.  
208 2016;**11**(11):e0166158.
- 209 9 Karat AS, Tlali M, Fielding KL, et al. Measuring mortality due to HIV-associated tuberculosis among adults in  
210 South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. Isaakidis P, editor. *PLoS*  
211 *One*. 2017;**12**(3):e0174097.
- 212 10 Fielding KL, Charalambous S, Hoffmann CJ, et al. Evaluation of a point-of-care tuberculosis test-and-treat  
213 algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study  
214 protocol for a cluster randomised controlled trial. *Trials*. 2015;**16**(1):125.
- 215 11 Cox JA, Lukande RL, Kalungi S, et al. Practice of percutaneous needle autopsy; a descriptive study reporting  
216 experiences from Uganda. *BMC Clin Pathol*. 2014;**14**(1):44.
- 217 12 Castillo P, Ussene E, Ismail MR, et al. Pathological Methods Applied to the Investigation of Causes of Death in  
218 Developing Countries: Minimally Invasive Autopsy Approach. *PLoS One*. 2015;**10**(6):e0132057.
- 219 13 World Health Organization. Guidance on regulations for the Transport of Infectious Substances 2015-2016.  
220 2015. [http://www.who.int/ihr/publications/who\\_hse\\_ihr\\_2015.2/en/](http://www.who.int/ihr/publications/who_hse_ihr_2015.2/en/) (accessed 2019 Feb 3)  
221  
222

224 Table 1. Suggested essential equipment for conducting an MIA in the field

Category / sub-category / item/s		Comments	
<b>Documentation</b>	Approvals from research ethics committee/s and national, provincial, and district department of health	All documentation that is handed to families or mortuary staff should be approved by oversight bodies and should include study team contact details	
	Plain-language summary of study aims and activities for families		
	Plain-language summary of study aims and activities for mortuary owners and staff		
	Formal information sheets and consent forms		
	Lab request forms		
<b>Personal protective equipment</b>	N95 mask	Suggested as a minimum set per person. Appropriate training around universal precautions and disposal of sharps should be conducted.	
	Goggles, visor, or other eye protection		
	Gown/apron		
	Non-sterile latex gloves		
	Alcohol gel		
	Hair net and shoe covers (or rubber boots)		
<b>Autopsy kit</b>	<b>Preparatory</b>	Headtorch	Medium for transportation of samples should be tailored to lab requirements.
		Folding work-surface/s	
		For cleaning: Povidone iodine; cold sterilant (min 150ml)*	
		For samples: Formalin; sterile saline	
	<b>Sharps</b>	Sharps bin	Suggest use of disposable equipment unless able to access sterilising facilities (cold sterilant* can be used to disinfect)
		Scalpel (small)	
		Tissue biopsy needles	
		18G hypodermic needles	
		Spinal needle/s	
		Skin sutures (nylon, 4-0)	
	<b>BAL/ CSF/ Blood/ Urine</b>	Surgical scissors	
		Catheter/s (male and female) <sup>†</sup>	
		Nasogastric tube/s <sup>‡</sup>	
		Syringes (20ml)	
		Sterile lubricating gel (sachets)	
<b>Other</b>	Sterile saline pack/s (200ml) <sup>‡</sup>		
	Sterile gauze; alcohol swabs; surgical forceps; needle-holder; plasters		
	Sterile gloves and sterile procedure kits (if needed)		
<b>Miscellaneous</b>	<b>Waste &amp; transport</b>	Waste bags (one for clinical waste, one for general waste)	See WHO/IATA guidelines for requirements around transportation and labelling of potentially infectious specimens
		Paper towels and cleaning fluid	
		Bio-bottles	
		Ice packs	
		Styrofoam insulation container	
	<b>Other</b>	Clipboard, pens, and permanent marker	
		Scissors and adhesive tape	
		Spare batteries (for headtorch)	

225 \*Can be used to disinfect (in ~5–10 minutes) or sterilise (in ~15–20 minutes, depending on manufacturer) steel  
226 instruments. <sup>†</sup>Required only if collecting urine. <sup>‡</sup>Required only if conducting modified broncho-alveolar lavage  
227 BAL: bronchoalveolar lavage; CSF: cerebrospinal fluid; IATA: International Air Transport Association; MIA: minimally-  
228 invasive autopsy; WHO: World Health Organization

230 **Figure 1. Overview of processes and interactions needed to obtain consent for and conduct MIA in a**  
 231 **private mortuary or other community location**



232 \*Sterile precautions required only if attempting to collect samples for bacteriology (e.g., microscopy or culture)  
 233 IATA: International Air Travel Association; MIA: minimally-invasive autopsy; WHO: World Health Organization  
 234